Capital International Sarl Raises Holdings in BeOne Medicines Ltd. – Sponsored ADR $ONC

Capital International Sarl increased its position in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 2.7% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 152,515 shares of the company’s stock after buying an additional 3,956 shares during the period. Capital International Sarl’s holdings in BeOne Medicines were worth $46,336,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in ONC. Bank of America Corp DE purchased a new position in shares of BeOne Medicines in the 2nd quarter worth $67,657,000. Man Group plc purchased a new position in shares of BeOne Medicines in the 2nd quarter worth $59,031,000. Capital International Investors raised its position in shares of BeOne Medicines by 3.3% in the 3rd quarter. Capital International Investors now owns 5,046,058 shares of the company’s stock worth $1,716,883,000 after buying an additional 161,052 shares during the period. BNP Paribas Financial Markets purchased a new position in shares of BeOne Medicines in the 2nd quarter worth $38,337,000. Finally, Qube Research & Technologies Ltd purchased a new position in shares of BeOne Medicines in the 2nd quarter worth $26,034,000. 48.55% of the stock is owned by hedge funds and other institutional investors.

BeOne Medicines Stock Down 3.5%

Shares of BeOne Medicines stock opened at $270.10 on Friday. The business has a 50-day moving average of $301.86 and a 200-day moving average of $317.87. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. The company has a market capitalization of $29.64 billion, a PE ratio of 60.43 and a beta of 0.49. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $239.25 and a 1-year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last announced its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. The company had revenue of $1.51 billion during the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. As a group, equities analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 EPS for the current fiscal year.

Analysts Set New Price Targets

ONC has been the topic of several research reports. Wolfe Research began coverage on BeOne Medicines in a research report on Friday, March 27th. They issued an “outperform” rating and a $340.00 target price on the stock. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Wells Fargo & Company began coverage on BeOne Medicines in a research report on Monday, May 4th. They issued an “overweight” rating and a $400.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th. Finally, Leerink Partners raised their price objective on BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a research report on Friday, May 15th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, BeOne Medicines presently has a consensus rating of “Moderate Buy” and a consensus target price of $390.00.

Insiders Place Their Bets

In other news, SVP Chan Henry Lee sold 332 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $310.72, for a total transaction of $103,159.04. Following the completion of the sale, the senior vice president directly owned 101 shares in the company, valued at $31,382.72. This trade represents a 76.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alessandro Riva sold 212 shares of the firm’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $309.51, for a total value of $65,616.12. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 1,641 shares of company stock valued at $505,791 over the last ninety days. Insiders own 6.19% of the company’s stock.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.